
Vinit B Mahajan,1,2 Mahita Kadmiel,2,3 Yoreh Barak,4,5 David RP Almeida2,3 1Molecular Surgery Laboratory, Byers Eye Institute, Stanford University, Palo Alto, CA, USA; 2The Centers for Advanced Surgical Exploration (CASEx), Miami, FL, USA; 3Erie Retina Research, Erie, PA, USA; 4Department of Ophthalmology, Rambam Health Care Campus, Haifa, Israel; 5Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, IsraelCorrespondence: David RP Almeida, The Centers for Advanced Surgical Exploration (CASEx), 1951 NW 7th Avenue, Suite 300, Miami, FL, 33136, USA, Email drpa@pm.meBackground: Developing novel ophthalmic devices is capital-intensive and high-risk, with the preclinical phase a principal driver of cost and attrition. We evaluate the projected economic impact of integrating a high-fidelity, reusable, chemically-engineered human-tissue specimen platform (Near-Real Surgical Specimens, NRSS, a physical bench-testing analog rather than a software simulation) into the device-development lifecycle. The analysis is a decision-analytic projection, not an empirical evaluation of implemented NRSS programs.Methods: We constructed a transparent multi-phase decision-tree model on a risk-adjusted (expected-value) net present value (NPV) basis, comparing a Traditional pathway with an NRSS-facilitated pathway for two representative devices. Baseline costs, durations, and transition success probabilities were drawn from published medical-device benchmarks; NRSS effects were entered as explicit, range-tested scenario assumptions, with the key de-risking assumption derived from published root-cause and predictive-model benchmarks. The 10% base-case discount rate reflects the commercial cost of capital in medical technology and is the convention for firm-level industry R&D decision models; results at 3% and 5% are additionally reported to align with health-economic social-discount practice. One-way (tornado), threshold, scenario, and probabilistic (Monte Carlo, 10,000 iterations) analyses followed CHEERS 2022 reporting standards. Full model equations, probability distributions, parameter ranges, correlation assumptions, and simulation code are provided as Supplementary Material.Results: Under the base-case assumptions, the NRSS-facilitated pathway reduced projected risk-adjusted capitalized cost by 21 to 22% (posterior: $470M to $371M; anterior: $245M to $191M), shortened projected time-to-market by approximately 1.25 years, and increased projected NPV by 49 to 50%. De-risking of the nonclinical-to-feasibility transition and revenue assumptions were the dominant value drivers. In a conservative scenario with the transition-probability improvement removed entirely, the NRSS advantage remained positive (approximately 13 to 14% capitalized-cost reduction) on consumable and timeline effects alone. The projected advantage was robust across 3 to 10% discount rates, persisted up to an implementation cost of approximately $42M, and held in essentially all of 10,000 probabilistic simulations (mean NPV improvement approximately $43M; 95% interval approximately $20 to 73M).Conclusion: Under the modeled assumptions, high-fidelity engineered-tissue platforms may improve the economics of ophthalmic device development, primarily by de-risking the preclinical-to-feasibility transition. These are projections, not demonstrated effect sizes, and the magnitude is highly sensitive to the assumed transition-probability improvement; absolute values should not be interpreted as expected real-world outcomes. Independent, prospective validation of both NRSS performance and the projected economic effects is an essential next step before translating these findings into investment or policy decisions.Keywords: economic modeling, medical device development, preclinical testing, technology commercialization, return on investment, health technology assessment
Julie Hartman,1 Luke Benda,1 John Costantine,2 Shaun Fant3 1Healing Innovations, Inc., Nashville, TN, USA; 2Post Acute Services, HCA Healthcare, Nashville, TN, USA; 3Methodist Hospital, San Antonio, TX, USACorrespondence: Julie Hartman, Healing Innovations, Inc., Nashville, TN, USA, Tel +1 615 965-5020 ext 704, Email julie@healinginnovations.comPurpose: Robotic-assisted gait training (RAGT) offers a technology-driven approach to support intensive rehabilitation and recovery following disabling stroke. This study evaluates clinical feasibility, safety surveillance, and descriptive within-stay functional changes in an inpatient cohort receiving the Rise&Walk® (end-effector RAGT [E-RAGT] device, donated by the manufacturer, Healing Innovations, Inc.) alongside standard physical therapy.Patients and Methods: In this single-cohort, retrospective pilot feasibility study, consecutive adult patients admitted for inpatient stroke rehabilitation underwent E-RAGT sessions using the study device. Outcomes included individual Section GG mobility items and balance and gait measures, including the Berg Balance Scale (BBS) and 10-meter walk test (10MWT), collected in a subset of patients.Results: Thirteen consecutive adult stroke patients (median age 66 years; 9 [69%] male) completed an average of 4.2 sessions (range 2– 8). Baseline Section GG scores reflected functional dependence, and all patients required assistance or supervision. Improvements were observed across all Section GG mobility items, with larger gains in walking tasks than stair negotiation. Balance (BBS) and gait speed (10MWT) measures were available for a subset of five patients, all demonstrating descriptive improvements. At discharge, four patients were fully independent across all mobility tasks, while three remained dependent on at least one item, primarily 12-step stair negotiation. Mean length of stay was 16.7 ± 5.2 days. Ten patients were discharged home; three were discharged to a skilled nursing facility with remaining dependence on at least one mobility item. No serious adverse events occurred.Conclusion: In this small, uncontrolled pilot cohort receiving concurrent standard physical therapy, end-effector RAGT with the study device demonstrated feasibility and safety, with within-stay descriptive improvements in mobility, balance, and gait. Controlled trials are required to establish treatment efficacy.Plain Language Summary: After having a stroke, many patients have difficulty walking. Relearning how to walk requires frequent practice and intense physical therapy, which can be physically demanding for rehabilitation staff. Robotic-assisted walking devices may help therapists provide more intensive training. In this small pilot study, we evaluated the feasibility of an end-effector robotic gait training system in 13 adults undergoing inpatient stroke rehabilitation alongside their standard physical therapy. We found that the technology was practical and feasible to use in routine hospital care, with all participants completing their sessions safely without any serious side effects or injuries. Patients showed improvements in walking and mobility during their rehabilitation stay across all assessed tasks, with the largest gains observed in walking activities. Importantly, the robotic device supported high-intensity, repetitive walking practice that is essential for stroke recovery. These preliminary findings show that end-effector robotic gait training is a practical and valuable tool for inpatient rehabilitation, while providing a foundation for the larger controlled trials needed to confirm long-term benefits.Keywords: End-effector robotic-assisted gait training, stroke rehabilitation, gait training, neurological rehabilitation, functional mobility
Sharad Rajpal,1 Arjun Joshi,2 Daniel Cher,3 David W Polly41Neurosurgery, AdventHealth, Louisville, CO, USA; 2Product Marketing, SI-BONE, Inc., San Jose, CA, USA; 3Regulatory Affairs, SI-BONE, Inc., San Jose, CA, USA; 4Department of Orthopedics, University of Minnesota, Minneapolis, MN, USACorrespondence: Daniel Cher, Regulatory Affairs, SI-BONE, Inc., 88. W. Plumeria Drive, San Jose, CA, 95134, USA, Email dcher@si-bone.comObjective: To determine whether use of intraoperative navigation is associated with a reduced rate of acute symptomatic implant malposition during iliosacral implant placement in sacroiliac (SI) joint fusion and sacral fracture fixation.Methods: Retrospective analysis of post-market databases regarding device use and reported device-related complaints from a single device manufacturer between March 2021 and August 2026 were combined, including procedure type, procedure date and use of navigation systems. Analysis focused on lateral and posterolateral (PL) transiliac placement of a porous threaded implant (PTI, iFuse TORQ) during SI joint fusion and sacral fracture fixation procedures performed in the USA. All acute symptomatic implant malpositions reported as product complaints were identified and linked to index surgeries through manual identification. The proportion of navigated and non-navigated cases that resulted in symptomatic implant malposition was compared using Firth’s penalized logistic regression test.Results: 25,096 procedures using 68,352 PTI were identified. Navigation was used in 15.6% (n=3,919) of cases. Implant malposition causing acute symptoms occurred in 63 cases (overall rate 0.25%). Of these, 2 occurred in navigated cases (rate, 0.05%) and 61 occurred in non-navigated cases (rate, 0.29%, odds ratio 0.22, 95% CI 0.046– 0.639, p=0.0014).Conclusion: Navigation was associated with a markedly lower rate of acute symptomatic implant malposition during lateral or PL transiliac placement of a PTI.Plain Language Summary: Sacroiliac joint fusion is a widely accepted and performed procedures. Implant placement can be guided fluoroscopically or by navigation systems. Navigation systems are generally thought to allow more accurate implant placement.A manufacturer reviewed reported instances of acute symptomatic implant malposition in > 25,000 cases of SI joint fusion or pelvic fracture fixation surgeries using a porous threaded implant (iFuse TORQ, SI-BONE, Inc). Implant malposition occurred in 61 cases (rate of 0.29%) guided fluoroscopically and 2 cases (rate of 0.05%) guided with navigation systems (odds ratio 0.220, p=0.0014). The large rate difference is unlikely to be due to underreporting. These findings support the use of navigation during pelvic surgery to reduce symptomatic implant malposition.Keywords: porous threaded implants, sacroiliac joint arthrodesis, navigation, stereotactic surgery, implant malposition